Yet, our results show that MYO10 mRNA expression ratio might represent a new promising prognostic factor for survival of LUSC patients, especially considering the fact that MYO10 was upregulated at the mRNA level in almost 30% of LUSC patients in the TCGA dataset, which is to our knowledge the highest rate of MYO10 upregulation among all the cancer entities reported in TCGA. The gene discussed is MYO10; the disease is cancer.